Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Nasdaq Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Nasdaq Inc trades at $85.14 (market cap $48.88B). The key difference: Nasdaq Inc is far larger — about 10.9× ACADIA Pharmaceuticals Inc.'s market cap, and Nasdaq Inc pays a 1.3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NDAQ | |
|---|---|---|
Market Cap | $4.49B | $48.88B |
Sector | Health | Financials |
52-Week High | $28.06 | $100.98 |
52-Week Low | $20.06 | $76.85 |
Enterprise Value | $3.69B | $55.94B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Nasdaq (NDAQ) trades at $86.43, up 2.09% with strong fundamental performance including 2025 revenue of $8.26B and net income of $1.79B. The stock shows bullish technical signals with support at $83 and resistance at $86, while maintaining consistent earnings beats in recent quarters. Recent news highlights Nasdaq's record trading volumes and strategic expansions.
Outlook remains positive with analyst consensus target of $103 (19% upside), though risks include market volatility sensitivity and competitive pressures. The company's dominant exchange position and growing IPO pipeline provide solid growth foundation for investors seeking financial services exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
